Non-peptide αvβ3 antagonists. Part 6: Design and synthesis of αvβ3 antagonists containing a pyridone or pyrazinone central scaffold

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 10, 2003, Pages 1809-1812

  Breslin, Michael J ^a   Duggan, Mark E ^a   Halczenko, Wasyl ^a   Fernandez Metzler, Carmen ^a   Hunt, Cecilia A ^a   Leu, Chih Tai ^a   Merkle, Kara M ^a   Naylor Olsen, Adel M ^a   Prueksaritanont, Thomayant ^a   Stump, Gary ^a   Wallace, Audrey ^a   Rodan, Sevgi B ^a   Hutchinson, John H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ALPHA5 INTEGRIN; BETA ALANINE; BETA3 INTEGRIN; DIPYRONE; FUNCTIONAL GROUP; INTEGRIN RECEPTOR; RECEPTOR BLOCKING AGENT;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 0038702062     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00254-3     Document Type: Article

References (17)

1. Sato M., Grese T.A., Dodge J.A., Bryant H.U., Turner C.H. J. Med. Chem. 42:1999;1.
2. Rodan S.B., Rodan G.A. J. Endocrinol. 154:1997;S47.
3. Duong L.T., Rodan G.A. Front. Biosci. 3:1997;d757.
4. (a) Hartman G.D., Duggan M.E. Exp. Opin. Invest. Drugs. 9:2000;1281
5. (b) Duggan M.E., Hutchinson J.H. Exp. Opin. Ther. Pat. 10:2000;1367.
6. (a) Yamamoto M., Fisher J.E., Gentile M., Seedor J.G., Leu C.-T., Rodan S.B., Rodan G.A. Endocrinology. 139:1998;1411
7. (b) Crippes B.A., Engleman V.W., Settle S.L., Delarco J., Ornberg R.L., Helfrich M.H., Horton M.A., Nickols G.A. Endocrinology. 137:1996;918
8. (c) Hoffman S.J., Vasko-Moser J., Miller W.H., Lark M.W., Gowen M., Stroup G. J. Pharm. Exp. 302:2002;205.
9. Meissner R.S., Perkins J.J., Duong L.T., Hartman G.D., Hoffman W.F., Huff J.R., Ihle N.C., Leu C.-T., Nagy R.M., Naylor-Olsen A.M., Rodan G.A., Rodan S.B., Whitman D.B., Wesolowski G.A., Duggan M.E. Bioorg. Med. Chem. Lett. 12:2002;25.
10. Coleman P.J., Brashear K.M., Hunt C.A., Hoffman W.F., Hutchinson J.H., Breslin M.J., McVean C.A., Askew B.C., Hartman G.D., Rodan S.B., Rodan G.A., Leu C.-T., Prueksaritanont T., Fernandez-Metzler C., Ma B., Libby L.A., Merkle K.M., Stump G.L., Wallace A.A., Lynch J.J., Lynch R., Duggan M.E. Bioorg. Med. Chem. Lett. 12:2002;31.
11. Hamill T.G., Duggan M.E., Perkins J.J. J. Label. Compd. Radiopharm. 44:2001;55.
12. Inhibition of ADP-stimulated aggregation of human gel-filtered platelets, see: Hutchinson J.H., Cook J.J., Brashear K.M., Breslin M.J., Glass J.D., Gould R.J., Halczenko W., Holahan M.A., Lynch R.J., Sitko G.R., Stranieri M.T., Hartman G.D. J. Med. Chem. 39:1996;4583.
13. Coleman P.J., Askew B.C., Hutchinson J.H., Whitman D.W., Perkins J.J., Hartman G.D., Rodan G.A., Leu C.-T., Prueksaritanont T., Fernandez-Metzler C., Merkle K.M., Lynch R., Lynch J.J., Rodan S.B., Duggan M.E. Bioorg. Med. Chem. Lett. 12:2002;2463.
14. Merck and Co. US Patent 5 981 546.
15. (a) Merck and Co. US Patent 5 668 289, 1997.
16. (b) Merck and Co. US Patent 5 981 546, 1999.
17. Sanderson P.E., Lyle T.A., Cutrona K.J., Dyer D.L., Dorsey B.D., McDonough C.M., Naylor-Olsen A.M., Chen I., Chen Z., Cook J.J., Cooper C.M., Gardell S.J., Hare T.R., Krueger J.A., Lewis S.D., Lin J.H., Lucas B.J., Lyle E.A., Lynch J.J., Straneri M.T., Vastag K., Yan Y., Shafer J.A., Vacca J.P. J. Med. Chem. 41:1998;4466.